Until recently shareholders were happily waiting for Lazard, an investment bank hired to produce a strategic review for Hollinger International, to get on with selling the company's assets for a big premium.
Matthew Osborne at Lazard Capital Markets raised his price target on Celgene slightly, arguing the boost given to Celgene's international presence and pipeline could outweigh the dilutive aspects of the deal.